JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

Incyte Corp

Отворен

СекторЗдравеопазване

89.78 -1.01

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

87.87

Максимум

94.32

Ключови измерители

By Trading Economics

Приходи

247M

405M

Продажби

163M

1.2B

P/E

Средно за сектора

20.714

37.461

Марж на печалбата

33.319

Служители

2,617

EBITDA

324M

582M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

-5.53% downside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

3.5B

17B

Предишно отваряне

90.79

Предишно затваряне

89.78

Настроения в новините

By Acuity

26%

74%

57 / 373 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Incyte Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.10.2025 г., 23:50 ч. UTC

Горещи акции

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28.10.2025 г., 23:25 ч. UTC

Печалби

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28.10.2025 г., 23:18 ч. UTC

Печалби

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28.10.2025 г., 22:20 ч. UTC

Печалби

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28.10.2025 г., 22:13 ч. UTC

Печалби

Wal-Mart de Mexico Net Profit Falls in 3Q

28.10.2025 г., 21:38 ч. UTC

Печалби

Correction to Visa Sales Jump Article

28.10.2025 г., 21:17 ч. UTC

Печалби

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28.10.2025 г., 21:07 ч. UTC

Печалби

Visa Sales Jump as Consumers Keep Spending -- Update

28.10.2025 г., 21:02 ч. UTC

Печалби

Mondelez Tempers Outlook as Costs Rise

28.10.2025 г., 23:51 ч. UTC

Пазарно говорене

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28.10.2025 г., 23:42 ч. UTC

Пазарно говорене

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28.10.2025 г., 23:02 ч. UTC

Печалби

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28.10.2025 г., 23:01 ч. UTC

Печалби

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28.10.2025 г., 22:46 ч. UTC

Печалби

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28.10.2025 г., 22:45 ч. UTC

Печалби

SK Hynix 3Q Net KRW12.6T >000660.SE

28.10.2025 г., 22:44 ч. UTC

Печалби

SK Hynix 3Q Rev KRW24.44T >000660.SE

28.10.2025 г., 22:43 ч. UTC

Печалби

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28.10.2025 г., 22:42 ч. UTC

Печалби

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28.10.2025 г., 22:40 ч. UTC

Печалби

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28.10.2025 г., 22:40 ч. UTC

Печалби

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28.10.2025 г., 22:22 ч. UTC

Печалби

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28.10.2025 г., 22:22 ч. UTC

Печалби

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28.10.2025 г., 22:22 ч. UTC

Печалби

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28.10.2025 г., 22:20 ч. UTC

Печалби

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28.10.2025 г., 22:02 ч. UTC

Печалби

Review & Preview: Earnings Extravaganza -- Barrons.com

28.10.2025 г., 21:42 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

28.10.2025 г., 21:42 ч. UTC

Пазарно говорене
Печалби

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28.10.2025 г., 21:20 ч. UTC

Печалби

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28.10.2025 г., 21:19 ч. UTC

Печалби

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28.10.2025 г., 21:18 ч. UTC

Печалби

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Сравнение с други в отрасъла

Ценова промяна

Incyte Corp Прогноза

Ценова цел

By TipRanks

-5.53% надолу

12-месечна прогноза

Среден 87.93 USD  -5.53%

Висок 115 USD

Нисък 60 USD

Според 18 анализатори от Wall Street, предложили 12-месечна ценова цел за Incyte Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

18 ratings

7

Купи

10

Задържане

1

Продай

Техническа оценка

By Trading Central

59.52 / 62.66Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

57 / 373 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
help-icon Live chat